176 related articles for article (PubMed ID: 31936647)
1. Bone Marrow Clonogenic Myeloid Progenitors from
Guardia RD; González-Silva L; López-Millán B; Rodríguez-Sevilla JJ; Baroni ML; Bueno C; Anguita E; Vives S; Palomo L; Lapillonne H; Varela I; Menendez P
Genes (Basel); 2020 Jan; 11(1):. PubMed ID: 31936647
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.
Ostronoff F; Othus M; Lazenby M; Estey E; Appelbaum FR; Evans A; Godwin J; Gilkes A; Kopecky KJ; Burnett A; List AF; Fang M; Oehler VG; Petersdorf SH; Pogosova-Agadjanyan EL; Radich JP; Willman CL; Meshinchi S; Stirewalt DL
J Clin Oncol; 2015 Apr; 33(10):1157-64. PubMed ID: 25713434
[TBL] [Abstract][Full Text] [Related]
3. Characterization of FLT3-ITD
Travaglini S; Angelini DF; Alfonso V; Guerrera G; Lavorgna S; Divona M; Nardozza AM; Consalvo MI; Fabiani E; De Bardi M; Neri B; Forghieri F; Marchesi F; Paterno G; Cerretti R; Barragan E; Fiori V; Dominici S; Del Principe MI; Venditti A; Battistini L; Arcese W; Lo-Coco F; Voso MT; Ottone T
Blood Cancer J; 2020 Aug; 10(8):85. PubMed ID: 32843624
[TBL] [Abstract][Full Text] [Related]
4. Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.
Flynn PA; Long MD; Kosaka Y; Long N; Mulkey JS; Coy JL; Agarwal A; Lind EF
Front Immunol; 2024; 15():1297338. PubMed ID: 38495876
[TBL] [Abstract][Full Text] [Related]
5. Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemia.
Pazhakh V; Zaker F; Alimoghaddam K; Atashrazm F
Ann Saudi Med; 2011; 31(1):45-50. PubMed ID: 21245599
[TBL] [Abstract][Full Text] [Related]
6. Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML.
Zhang B; Nguyen LXT; Zhao D; Frankhouser DE; Wang H; Hoang DH; Qiao J; Abundis C; Brehove M; Su YL; Feng Y; Stein A; Ghoda L; Dorrance A; Perrotti D; Chen Z; Han A; Pichiorri F; Jin J; Jovanovic-Talisman T; Caligiuri MA; Kuo CJ; Yoshimura A; Li L; Rockne RC; Kortylewski M; Zheng Y; Carlesso N; Kuo YH; Marcucci G
J Hematol Oncol; 2021 Aug; 14(1):122. PubMed ID: 34372909
[TBL] [Abstract][Full Text] [Related]
7. Blasts with folded nuclei: A histopathologic finding in myeloid leukemia cutis with NPM1 and FLT3 mutations.
Han S; Patel T; Garcia ML; Tirado M
J Cutan Pathol; 2024 Feb; 51(2):130-134. PubMed ID: 37866827
[TBL] [Abstract][Full Text] [Related]
8. [ITD mutation burden for the prognosis in FLT3-ITD positive acute myeloid leukemia patients].
Ding S; Shen H; Chen Z; Chen S; Cen J; Ding Z; He J
Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):449-54. PubMed ID: 26134006
[TBL] [Abstract][Full Text] [Related]
9. The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis.
Tsapogas P; Mooney CJ; Brown G; Rolink A
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28538663
[TBL] [Abstract][Full Text] [Related]
10. Chronic FLT3-ITD Signaling in Acute Myeloid Leukemia Is Connected to a Specific Chromatin Signature.
Cauchy P; James SR; Zacarias-Cabeza J; Ptasinska A; Imperato MR; Assi SA; Piper J; Canestraro M; Hoogenkamp M; Raghavan M; Loke J; Akiki S; Clokie SJ; Richards SJ; Westhead DR; Griffiths MJ; Ott S; Bonifer C; Cockerill PN
Cell Rep; 2015 Aug; 12(5):821-36. PubMed ID: 26212328
[TBL] [Abstract][Full Text] [Related]
11. Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.
Falini B; Dillon R
Blood Cancer Discov; 2024 Jan; 5(1):8-20. PubMed ID: 37917833
[TBL] [Abstract][Full Text] [Related]
12. Gene regulation in t(6;9) DEK::NUP214 Acute Myeloid Leukemia resembles that of FLT3-ITD/NPM1 Acute Myeloid Leukemia but with an altered HOX/MEIS axis.
Potluri S; Kellaway SG; Coleman DJL; Keane P; Imperato MR; Assi SA; Cockerill PN; Bonifer C
Leukemia; 2024 Feb; 38(2):403-407. PubMed ID: 38172329
[No Abstract] [Full Text] [Related]
13. Evaluation of hypereosinophilia in a case of
Martinez-Gutierrez LN; Burgher BC; Glynias MJ; Alvarado D; Griffiths EA; Glenn ST; Sung PJ
Cold Spring Harb Mol Case Stud; 2023 Jun; 9(3):. PubMed ID: 37433680
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and Outcome of FLT3-ITD-Positive Pediatric Acute Myeloid Leukemia-Experience of Polish Pediatric Leukemia and Lymphoma Study Group from 2005 to 2022.
Czogała M; Czogała W; Pawińska-Wąsikowska K; Książek T; Bukowska-Strakova K; Sikorska-Fic B; Łaguna P; Fałkowska A; Drabko K; Muszyńska-Rosłan K; Krawczuk-Rybak M; Kozłowska M; Irga-Jaworska N; Zielezińska K; Urasiński T; Bartoszewicz N; Styczyński J; Skalska-Sadowska J; Wachowiak J; Rodziewicz-Konarska A; Kałwak K; Ciebiera M; Chaber R; Mizia-Malarz A; Chodała-Grzywacz A; Karolczyk G; Bobeff K; Młynarski W; Mycko K; Badowska W; Tomaszewska R; Szczepański T; Machnik K; Zamorska N; Balwierz W; Skoczeń S
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760526
[TBL] [Abstract][Full Text] [Related]
15. The clinicopathologic significance of NPM1 mutation and ability to detect mutated NPM1 by immunohistochemistry in non-AML myeloid neoplasms.
Kaseb H; Visconte V; Socha DS; Crane GM; Durkin L; Cook JR; Maciejewski JP; Hsi ED; Rogers HJ
Genes Chromosomes Cancer; 2023 Oct; 62(10):573-580. PubMed ID: 36959701
[TBL] [Abstract][Full Text] [Related]
16. FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
Seipel K; Mandhair H; Bacher U; Pabst T
Curr Issues Mol Biol; 2024 Mar; 46(4):2946-2960. PubMed ID: 38666914
[TBL] [Abstract][Full Text] [Related]
17. Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients.
Shi Y; Chen X; Jin H; Zhu L; Hong M; Zhu Y; Wu Y; Qiu H; Wang Y; Sun Q; Jin H; Li J; Qian S; Qiao C
Ann Hematol; 2024 May; ():. PubMed ID: 38722387
[TBL] [Abstract][Full Text] [Related]
18. Day-21 bone marrow findings incorrectly designate residual leukaemia in FLT3-mutated acute myeloid leukaemia treated with intensive induction plus midostaurin: a morphology-focused study.
Tedjaseputra A; Roy S; Htun K; Oh D; McQuilten Z; Yeh P; Bennett A; Low MSY; Chunilal S; Wood EM; Shortt J
Pathology; 2024 Jun; 56(4):548-555. PubMed ID: 38580614
[TBL] [Abstract][Full Text] [Related]
19. Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia.
Oya S; Ozawa H; Maehiro Y; Nakamura T; Takaki Y; Fukuyama T; Yamasaki Y; Yamaguchi M; Aoyama K; Mouri F; Nagafuji K
Leuk Res; 2023 Jul; 130():107313. PubMed ID: 37207502
[No Abstract] [Full Text] [Related]
20. FLT3-targeted therapy restores GATA1 pathway function in NPM1/FLT3-ITD mutated acute myeloid leukaemia.
Sorcini D; Stella A; Scialdone A; Sartori S; Marra A; Rossi R; De Falco F; Adamo FM; Dorillo E; Geraci C; Arcaleni R; Rompietti C; Esposito A; Moretti L; Mameli MG; Martelli MP; Falini B; Sportoletti P
EJHaem; 2023 Nov; 4(4):1100-1104. PubMed ID: 38024637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
